期刊文献+

HBV相关性慢加急性肝衰竭患者短期预后模型的建立与评估 被引量:1

Establishment and evaluation of a short-term prognosis model in HBV-associated acute on chronic liver failure
下载PDF
导出
摘要 目的探讨影响HBV相关性慢加急性肝衰竭(HBV-ACLF)患者短期生存预后的危险因素并建立预后模型。方法收集72例HBV-ACLF患者临床资料,根据90 d生存情况分为生存组(33例)和死亡组(39例),采用logistic回归分析危险因素,并构建预后预测模型。结果死亡组年龄、中性粒/淋巴细胞比值及血清谷丙转氨酶、总胆红素、乳酸、C反应蛋白、C反应蛋白/白蛋白比值、胱抑素C、D-二聚体水平均显著高于生存组,而Na+、凝血酶原活动度显著低于生存组。血清总胆红素、胱抑素C、乳酸及D-二聚体是不良预后的独立危险因素。ROC曲线提示,TCLD模型的诊断效能优于终末期肝病模型。结论TCLD模型对HBV-ACLF患者90 d预后具有较好预测价值。 Objective To investigate the risk factors for short-term survival and establish a prognostic model in HBV associated acute on chronic liver failure(HBV-ACLF).Methods Clinical data of 72 patients with HBV-ACLF were collected and divided into death(n=39)and survival groups(n=33)according to 90-day survival.The risk factors were analyzed by logistic regression,and a prognostic model was constructed.Results Compared with survival group,age,neutrophil//lymphocyte ratio,and serum levels of alanine transaminase,total bilirubin(TBIL),lactic acid(LA),C-reactive protein,C-reactive protein/albumin ratio,cystatin C(CysC),and D-dimer were higher,while Na+and prothrombin activity were lower in death group.TBIL,CysC,LA and D-dimer were independent risk factors for poor prognosis.The ROC curve indicated that the diagnostic efficiency of TCLD model was superior to that of Model for End Stage Liver Disease(MELD).Conclusion TCLD model could be effective for predicting 90-day prognosis of HBV-ACLF patients.
作者 巴志伟 詹步同 刘传苗 BA Zhi-wei;ZHAN Bu-tong;LIU Chuan-miao(First Affiliated Hospital of Bengbu Medical College,Bengbu 233000,China)
出处 《广东医科大学学报》 2022年第1期70-74,共5页 Journal of Guangdong Medical University
关键词 慢加急性肝衰竭 危险因素 预后 acute-on-chronic liver failure risk factor prognosis
  • 相关文献

参考文献6

二级参考文献36

  • 1Zhi-Hong Wan,Jian-Jun Wang,Shao-Li You,Hong-Ling Liu,Bing Zhu,Hong Zang,Chen Li,Jing Chen,Shao-Jie Xin.Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure[J].World Journal of Gastroenterology,2013,19(48):9432-9438. 被引量:21
  • 2OKAGAWA Y, TAKADA K, HISAIH, et al. Successful treatment with entecavir for reactivation of hepatitis B virus following sys- temic chemotherapy in a hepatitis B surface antigen-negative pa- tient with colorectal cancer[J]. Intern Med, 2014, 53(16): 1759- 1762. 被引量:1
  • 3OZARAS R, METE B, CEYLANB, et al. First-line monothera- pies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment[J]. Eur J Gastroenterol Hepatol. 2014, 26 (7): 774-780. 被引量:1
  • 4SHOUVALD. The pros and cons of lamivudine vs. entecavir indecompensated or severe acute exacerbation of chronic hepatitis B[J]. J Hepatol, 2014, 60(6): 1108-1109. 被引量:1
  • 5TSAI WL, CHIANG PH, CHAN HH, et al. Early entecavir treatment for chronic hepatitis B with severe acute exacerbation [J]. Antimicrob Agents Chemother, 2014, 58(4): 1918-1921. 被引量:1
  • 6MIQUEL M, NUI~IEZ0, TRAPERO-MARUGANM, et al. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensat- ed and decompensated cirrhotic patients in clinical practice[J]. Ann Hepatol, 2013, 12(2): 205-212. 被引量:1
  • 7TANAKA H, SAKUMA I, HASHIMOTO S, et al. Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy : case report[J]. J Clin Exp Hematop, 2012, 52(1): 67-69. 被引量:1
  • 8AOUDJANE S, CHAPONDA M, GONZ?LEZ DEL CASTILLO AA, et al. Hepatitis B virus sub-genotype A1 infection is char- aeterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in malawi[J]. Clin Infect Dis, 2014, 59(11): 1618-1626. 被引量:1
  • 9MCMAHON B J, BULKOW L, SIMONS B, et al. Relationship between level of hepatitis B virus DNA and liver disease: a population-based study of hepatitis B e antigen-negative persons with hepatitis B[J]. ClinGastroenterol Hepatol, 2014, 12(4): 701- 706. 被引量:1
  • 10肖寒,马陈斌,张利霞,罗永燕,刘尹正泽,邵婕.恩替卡韦对慢性乙型肝炎患者血清中HBVDNA载量与TGF-β_1的影响[J].南方医科大学学报,2012,32(4):589-592. 被引量:36

共引文献561

同被引文献12

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部